Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 4—April 2020

Severe Fever with Thrombocytopenia Syndrome, Japan, 2013–2017

Yusuke Kobayashi1, Hirofumi Kato, Takuya Yamagishi, Tomoe Shimada, Tamano Matsui, Tomoki Yoshikawa, Takeshi Kurosu, Masayuki Shimojima, Shigeru Morikawa2, Hideki Hasegawa, Masayuki Saijo, Kazunori Oishi3Comments to Author , and SFTS Epidemiological Research Group Japan
Author affiliations: National Institute of Infectious Diseases, Tokyo, Japan

Main Article

Table 2

Multivariable analysis of prognostic factors for 133 patients with severe fever with thrombocytopenia syndrome, Japan, March 2013–October 2017*

Variable Univariable
OR (95% CI) p value OR (95% CI) p value
Age NA 0.015 1.07 (0.98–1.16) 0.115
Malignant tumor 6.13 (1.45–26.04) 0.006 20.83 (1.32–327.70) 0.031
Disorientation 1.58 (0.71–3.52) 0.259 1.37 (0.30–6.35) 0.687
Tremor 8.60 (1.57–47.04) 0.004 17.37 (1.26–239.39) 0.033
Platelet NA 0.661 1.38 (1.07–1.78) 0.014
Albumin NA 0.791 0.99 (0.15–6.62) 0.994
ALT NA 0.015 1.01 (1.00–1.02) 0.371
LDH NA 0.012 1.00 (1.00–1.00) 0.378
CK NA 0.591 1.00 (1.00–1.00) 0.842
APTT NA 0.007 1.06 (0.97–1.16) 0.215

*ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; CK, creatine kinase; LDH, lactate dehydrogenase; NA, not applicable; OR, odds ratio.

Main Article

1Current affiliation: Saitama Prefectural Government, Saitama, Japan.

2Current affiliation: Okayama University of Science, Ehime, Japan.

3Current affiliation: Toyama Institute of Health, Toyama, Japan.

4Group members are listed at the end of the article.

Page created: March 17, 2020
Page updated: August 10, 2020
Page reviewed: August 10, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.